Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. On July 21, 2023, Verrica’s lead product, YCANTH^® (cantharidin) topical solution 0.7%, became the first treatment approved by the FDA to treat adult and pediatric patients as young as two years of age with molluscum contagiosum, a highly contagious, viral skin disease infection affecting approximately 6 million people in the United States, primarily children.

Please see Important Safety Information and full Prescribing Information for YCANTH.

Verrica has also entered a worldwide license agreement with Lytix Biopharma AS (“Lytix”) to develop and commercialize VP-315 for dermatologic oncology conditions. Verrica intends to focus initially on basal cell (BCC) and squamous cell carcinomas as the lead indication for development.

Verrica is currently focusing our efforts on (i) the commercialization of YCANTH (VP-102) for the treatment of molluscum, (ii) the development of YCANTH (VP-102) for the treatment of common warts and (iii) the development of VP-315 for the treatment of dermatology oncologic conditions, including BCC. Verrica is not currently advancing the development of VP-102 for the treatment of external genital warts or VP-103 for the treatment of plantar warts.